Editorial

Evidence-based Psychiatry: Outcomes and Decisions

Authors: Jonathan M. Meyer, MD

Abstract

The accompanying paper presented in this issue of the Southern Medical Journal reinforces concepts of data analysis that are of great importance for clinical psychiatrists. Despite enormous advances in the biologic understanding of mental illness, psychiatry remains an empirical medical specialty, whose outcomes data often cannot be interpreted in light of conceptual models of pathophysiology. The absence of specific biologic measures for clinical outcomes has forced the field to create empirically derived assessments with varying levels of clinical relevance. The advent of the DSM-III (Diagnostic and Statistical Manual) in 1980 heralded the era of empiricism in psychiatry, whereby disease states were (ideally) defined by common phenomenology, and not on psychoanalytically based conceptualizations for psychosis, mood disorders, or anxiety. DSM-III was supposed to use an atheoretical approach to diagnosis, but even such approaches require a theoretical model of disease in which the natural continua of psychopathology are divided into normal/abnormal by the simple act of defining a disease as 5 of 9 symptoms (eg, for major depression) instead of 4 of 9. Nonetheless, DSM was a boon to psychiatric research by establishing a common vocabulary for disorders, and thereby furthering the refinement of instruments to assess treatment outcomes.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Goldner EM, Bilsker D. Evidence-based psychiatry. Can J Psychiatry 1995;40:97–101.
 
2. Geddes JR, Game D, Jenkins NE, et al. What proportion of primary psychiatric interventions are based on evidence from randomised controlled trials? Qual Health Care 1996;5:215–217.
 
3. Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2000;2:CD000059.
 
4. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–1223.
 
5. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600–610.
 
6. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611–622.
 
7. Essock S, Covell N, Davis S, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006;163:2090–2095.
 
8. Citrome L. Show me the evidence: using number needed to treat. South Med J 2007;100:881–884.